Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
The NIF mouse in Cyma Bay preclinical study using Seladelpar
We are happy and proud that our NIF mouse is the model used in the preclinical poster presented by Cymabay Therapeutics at the upcoming AASLD meeting, with the title "Seladelpar reduces established liver and renal [...]
Take a look at InfiCures poster from the EASL NAFLD Summit!
InfiCure Bio attended the EASL NAFLD Summit in September, and presented this poster with up-to-date data on the NIF mouse.
Lena Söderström speaks at LXS Nordic Congress 8th of September
Lena Söderström, Head of board at InfiCureBio, will share her views on listing of companies. Take the opportunity to listen to her experiences!
InfiCure Bio will participate with a poster at EASL NAFLD Summit on September 16-17
Inficure Bio will attend the EASLE NAFLD Summit, and present a poster on the NIF mouse. Don't miss the opportunity to take part of the latest updates on how to use the NIF mouse for [...]